Skip to main content
. Author manuscript; available in PMC: 2018 Apr 23.
Published in final edited form as: Oncogene. 2017 Oct 23;37(7):944–952. doi: 10.1038/onc.2017.400

Figure 4. Effects of targeted inhibitors on viability of BRAF, NRAS, and RAC1-mutant melanoma cell lines.

Figure 4

Cells were grown under standard conditions and treated with either A) PAK inhibitor Frax-1036 (100 nM), B) the BRAF inhibitor vemurafenib (100 nM), C) the MEK inhibitor PD325901 (100 nM), or D) the RAC inhibitor NSC23766 (1 µM). Cell viability was determined by a redox indicator (Alamar Blue).